GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

Hepatocellular carcinoma is the most frequent primary liver cancer. Macroautophagy/autophagy inhibitors have been extensively studied in cancer but, to date, none has reached efficacy in clinical trials. In this study, we demonstrated that GNS561, a new autophagy inhibitor, whose anticancer activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Brun, Sonia, Bestion, Eloïne, Raymond, Eric, Bassissi, Firas, Jilkova, Zuzana Macek, Mezouar, Soraya, Rachid, Madani, Novello, Marie, Tracz, Jennifer, Hamaï, Ahmed, Lalmanach, Gilles, Vanderlynden, Lise, Legouffe, Raphael, Stauber, Jonathan, Schubert, Thomas, Plach, Maximilian G., Courcambeck, Jérôme, Drouot, Cyrille, Jacquemot, Guillaume, Serdjebi, Cindy, Roth, Gael, Baudoin, Jean-Pierre, Ansaldi, Christelle, Decaens, Thomas, Halfon, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037544/
https://www.ncbi.nlm.nih.gov/pubmed/34740311
http://dx.doi.org/10.1080/15548627.2021.1988357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037544/
https://www.ncbi.nlm.nih.gov/pubmed/34740311
http://dx.doi.org/10.1080/15548627.2021.1988357

Ejemplares similares